NYSE:AMRX Amneal Pharmaceuticals (AMRX) Stock Forecast, Price & News $2.55 +0.04 (+1.59%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$2.44▼$2.6050-Day Range$1.33▼$2.5752-Week Range$1.24▼$3.71Volume1.13 million shsAverage Volume897,403 shsMarket Capitalization$778.90 millionP/E RatioN/ADividend YieldN/APrice Target$3.60 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Amneal Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside41.2% Upside$3.60 Price TargetShort InterestHealthy4.61% of Float Sold ShortDividend StrengthN/ASustainability-2.51Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings Growth20.00%From $0.40 to $0.48 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.72 out of 5 starsMedical Sector58th out of 980 stocksPharmaceutical Preparations Industry22nd out of 485 stocks 3.4 Analyst's Opinion Consensus RatingAmneal Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.60, Amneal Pharmaceuticals has a forecasted upside of 41.2% from its current price of $2.55.Amount of Analyst CoverageAmneal Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted4.61% of the float of Amneal Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAmneal Pharmaceuticals has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in Amneal Pharmaceuticals has recently decreased by 24.76%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAmneal Pharmaceuticals does not currently pay a dividend.Dividend GrowthAmneal Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAmneal Pharmaceuticals has received a 47.20% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services", "Capecitabine", "Low-ceiling diuretics", "Memantine", "Arsenic trioxide", and "Hydroxychloroquine" products. See details.Environmental SustainabilityThe Environmental Impact score for Amneal Pharmaceuticals is -2.51. Previous Next 1.4 News and Social Media Coverage News SentimentAmneal Pharmaceuticals has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Amneal Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 30 people have searched for AMRX on MarketBeat in the last 30 days. This is a decrease of -12% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amneal Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders26.56% of the stock of Amneal Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 32.79% of the stock of Amneal Pharmaceuticals is held by institutions. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Amneal Pharmaceuticals are expected to grow by 20.00% in the coming year, from $0.40 to $0.48 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amneal Pharmaceuticals is -2.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Amneal Pharmaceuticals is -2.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioAmneal Pharmaceuticals has a PEG Ratio of 0.25. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioAmneal Pharmaceuticals has a P/B Ratio of 5.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Amneal Pharmaceuticals (NYSE:AMRX) StockAmneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generic, Specialty and AvKARE Segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The AvKARE segment focuses on pharmaceuticals, medical and surgical products, and services primarily to governmental agencies. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ.Read More Receive AMRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amneal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AMRX Stock News HeadlinesMay 29, 2023 | finance.yahoo.comAmneal Pharmaceuticals (NYSE:AMRX) shareholders have endured a 88% loss from investing in the stock five years agoMay 24, 2023 | finance.yahoo.comAmneal to Participate at the 2023 Jefferies Healthcare ConferenceJune 4, 2023 | MarketBeat Internal (Ad)Your Ultimate Investment Research PlatformMarketBeat All-Access is the all-in-one stock research solution that saves you time and helps you make more money. You get our top stock picks, best-in-class research tools, proprietary research reports and much more. May 24, 2023 | americanbankingnews.comAmneal Pharmaceuticals (NYSE:AMRX) Shares Down 2.2% May 24, 2023 | americanbankingnews.comAmneal Pharmaceuticals (NASDAQ:AMRX) Shares Down 2.2% May 23, 2023 | americanbankingnews.comAmneal Pharmaceuticals, Inc. (NYSE:AMRX) Receives $3.60 Average Price Target from AnalystsMay 20, 2023 | americanbankingnews.comAmneal Pharmaceuticals (NASDAQ:AMRX) Now Covered by StockNews.comMay 16, 2023 | finance.yahoo.comAmneal Launches Third Biosimilar with FYLNETRA™ (pegfilgrastim-pbbk) in the United StatesJune 4, 2023 | MarketBeat Internal (Ad)Your Ultimate Investment Research PlatformMarketBeat All-Access is the all-in-one stock research solution that saves you time and helps you make more money. You get our top stock picks, best-in-class research tools, proprietary research reports and much more. May 11, 2023 | americanbankingnews.comAmneal Pharmaceuticals' (AMRX) Maintains Rating Reiterated at 500.comMay 10, 2023 | markets.businessinsider.comAmneal Pharmaceuticals (AMRX) Gets a Buy from Goldman SachsMay 10, 2023 | americanbankingnews.comStockNews.com Upgrades Amneal Pharmaceuticals (NASDAQ:AMRX) to BuyMay 10, 2023 | americanbankingnews.comAmneal Pharmaceuticals (NYSE:AMRX) Rating Increased to Buy at StockNews.comMay 10, 2023 | americanbankingnews.comAmneal Pharmaceuticals (NYSE:AMRX) Shares Gap Up After Better-Than-Expected EarningsMay 9, 2023 | americanbankingnews.comPiper Sandler Cuts Amneal Pharmaceuticals (NYSE:AMRX) Price Target to $3.00May 8, 2023 | msn.comPiper Sandler Maintains Amneal Pharmaceuticals Inc - (AMRX) Overweight RecommendationMay 7, 2023 | finance.yahoo.comAmneal Pharmaceuticals, Inc. (NYSE:AMRX) Q1 2023 Earnings Call TranscriptMay 7, 2023 | americanbankingnews.comAmneal Pharmaceuticals (NYSE:AMRX) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPSMay 5, 2023 | finance.yahoo.comQ1 2023 Amneal Pharmaceuticals Inc Earnings CallMay 5, 2023 | seekingalpha.comAmneal Pharmaceuticals, Inc. (AMRX) Q1 2023 Earnings Call TranscriptMay 5, 2023 | msn.comAmneal Pharma Q1 Exceeds Consensus View On Strength In Complex Generics PortfolioMay 5, 2023 | seekingalpha.comAmneal Pharmaceuticals, Inc. 2023 Q1 - Results - Earnings Call PresentationMay 5, 2023 | msn.comRecap: Amneal Pharmaceuticals Q1 EarningsMay 5, 2023 | finance.yahoo.comAmneal Reports First Quarter 2023 Financial ResultsMay 4, 2023 | msn.comAmneal Pharmaceuticals Q1 2023 Earnings PreviewMay 4, 2023 | msn.comEarnings Preview: Amneal PharmaceuticalsMay 4, 2023 | americanbankingnews.comAmneal Pharmaceuticals (AMRX) Set to Announce Earnings on FridaySee More Headlines AMRX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AMRX Company Calendar Last Earnings5/05/2023Today6/04/2023Next Earnings (Estimated)8/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:AMRX CUSIPN/A CIK1723128 Webwww.amneal.com Phone(908) 947-3120Fax908-947-3146Employees7,600Year FoundedN/APrice Target and Rating Average Stock Price Forecast$3.60 High Stock Price Forecast$4.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+41.2%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.90) Trailing P/E RatioN/A Forward P/E Ratio6.38 P/E Growth0.25Net Income$-129,990,000.00 Net Margins-5.93% Pretax Margin-10.90% Return on Equity107.13% Return on Assets4.79% Debt Debt-to-Equity Ratio19.32 Current Ratio1.86 Quick Ratio1.11 Sales & Book Value Annual Sales$2.21 billion Price / Sales0.35 Cash Flow$1.42 per share Price / Cash Flow1.80 Book Value$0.44 per share Price / Book5.80Miscellaneous Outstanding Shares305,450,000Free Float224,325,000Market Cap$778.90 million OptionableOptionable Beta1.32 Key ExecutivesChintu PatelCo-Chief Executive Officer & DirectorChirag K. PatelPresident & Co-Chief Executive Officer & DirectorAnastasios G. KonidarisExecutive VP, Chief Financial & Accounting OfficerNikita ShahChief Human Resources Officer & Executive VPAndrew S. BoyerChief Commercial Officer-Generics & Executive VPKey CompetitorsDyne TherapeuticsNASDAQ:DYNCollegium PharmaceuticalNASDAQ:COLLArcturus TherapeuticsNASDAQ:ARCTAvidity BiosciencesNASDAQ:RNAPureTech HealthNASDAQ:PRTCView All CompetitorsInsiders & InstitutionsAmeriprise Financial Inc.Bought 31,901 shares on 5/22/2023Ownership: 0.039%JPMorgan Chase & Co.Bought 8,295 shares on 5/18/2023Ownership: 0.104%New York State Common Retirement FundSold 29,955 shares on 5/18/2023Ownership: 0.011%Susquehanna Fundamental Investments LLCSold 8,060 shares on 5/16/2023Ownership: 0.020%Susquehanna International Group LLPSold 7,100 shares on 5/16/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions AMRX Stock - Frequently Asked Questions Should I buy or sell Amneal Pharmaceuticals stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amneal Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AMRX shares. View AMRX analyst ratings or view top-rated stocks. What is Amneal Pharmaceuticals' stock price forecast for 2023? 4 Wall Street research analysts have issued twelve-month price targets for Amneal Pharmaceuticals' stock. Their AMRX share price forecasts range from $3.00 to $4.00. On average, they anticipate the company's share price to reach $3.60 in the next year. This suggests a possible upside of 41.2% from the stock's current price. View analysts price targets for AMRX or view top-rated stocks among Wall Street analysts. How have AMRX shares performed in 2023? Amneal Pharmaceuticals' stock was trading at $1.99 at the beginning of 2023. Since then, AMRX stock has increased by 28.1% and is now trading at $2.55. View the best growth stocks for 2023 here. Are investors shorting Amneal Pharmaceuticals? Amneal Pharmaceuticals saw a decrease in short interest during the month of April. As of April 30th, there was short interest totaling 6,220,000 shares, a decrease of 9.9% from the April 15th total of 6,900,000 shares. Based on an average daily volume of 1,010,000 shares, the short-interest ratio is currently 6.2 days. Approximately 6.3% of the company's stock are sold short. View Amneal Pharmaceuticals' Short Interest. When is Amneal Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 4th 2023. View our AMRX earnings forecast. How were Amneal Pharmaceuticals' earnings last quarter? Amneal Pharmaceuticals, Inc. (NYSE:AMRX) posted its earnings results on Friday, May, 5th. The company reported $0.10 earnings per share for the quarter, topping analysts' consensus estimates of $0.09 by $0.01. The firm had revenue of $557.54 million for the quarter, compared to the consensus estimate of $555 million. Amneal Pharmaceuticals had a positive trailing twelve-month return on equity of 107.13% and a negative net margin of 5.93%. During the same period in the previous year, the company posted $0.10 earnings per share. What guidance has Amneal Pharmaceuticals issued on next quarter's earnings? Amneal Pharmaceuticals issued an update on its FY 2023 earnings guidance on Friday, April, 21st. The company provided EPS guidance of $0.40-$0.50 for the period, compared to the consensus estimate of $0.50. The company issued revenue guidance of $2.25 billion-$2.35 billion, compared to the consensus revenue estimate of $2.31 billion. What is Chirag and Chintu Patel's approval rating as Amneal Pharmaceuticals' CEO? 23 employees have rated Amneal Pharmaceuticals Chief Executive Officer Chirag and Chintu Patel on Glassdoor.com. Chirag and Chintu Patel has an approval rating of 91% among the company's employees. This puts Chirag and Chintu Patel in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Amneal Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Amneal Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Teva Pharmaceutical Industries (TEVA), Cisco Systems (CSCO), Micron Technology (MU), General Electric (GE), OPKO Health (OPK), Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV) and Bausch Health Companies (BHC). What is Amneal Pharmaceuticals' stock symbol? Amneal Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "AMRX." Who are Amneal Pharmaceuticals' major shareholders? Amneal Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (2.38%), AQR Capital Management LLC (0.99%), State Street Corp (0.70%), Allspring Global Investments Holdings LLC (0.63%), Geode Capital Management LLC (0.62%) and Dimensional Fund Advisors LP (0.44%). Insiders that own company stock include Chirag K Patel, Gautam Patel, Joseph Todisco, Nikita Shah and Tpg Gp A, Llc. View institutional ownership trends. How do I buy shares of Amneal Pharmaceuticals? Shares of AMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Amneal Pharmaceuticals' stock price today? One share of AMRX stock can currently be purchased for approximately $2.55. How much money does Amneal Pharmaceuticals make? Amneal Pharmaceuticals (NYSE:AMRX) has a market capitalization of $778.90 million and generates $2.21 billion in revenue each year. The company earns $-129,990,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis. How many employees does Amneal Pharmaceuticals have? The company employs 7,600 workers across the globe. How can I contact Amneal Pharmaceuticals? Amneal Pharmaceuticals' mailing address is 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807. The official website for the company is www.amneal.com. The company can be reached via phone at (908) 947-3120, via email at invest@amneal.com, or via fax at 908-947-3146. This page (NYSE:AMRX) was last updated on 6/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amneal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.